ArticleFrontiers in microbiology2026
Metagenome analysis reveals multi-kingdom gut microbiota as diagnostic markers for colorectal cancer.
Article in Frontiers in microbiology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: Colorectal cancer (CRC) is a major contributor to cancer-related morbidity and mortality globally. Emerging evidence suggests that gut microbiota plays a pivotal role in CRC development. However, the precise link between CRC and gut microbial dysbiosis remains poorly understood. Methods: In this study, we analyzed metagenomic datasets from 578 samples, sourced from five geographically distinct cohorts, including CRC patients and healthy controls from China, Austria, and Spain. This diverse cohort enabled us to investigate changes in the gut microbiome-bacteria, viruses, fungi, and archaea-in CRC patients across varying genetic and environmental contexts. Results: Our analysis led to the identification of 12 bacterial, 18 viral, and 1 fungal marker using a diagnostic model based on the gut microbiome. Notably, the multi-kingdom model, incorporating these markers, outperformed single-domain models in diagnostic accuracy. Integrating 24 microbial markers-comprising 9 bacterial, 14 viral, and 1 fungal marker-yielded an impressive AUROC of 0.911 for CRC diagnosis. Conclusion: This model demonstrated robust performance across four independent cohorts, confirming its potential as a highly accurate, non-invasive diagnostic tool for CRC.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.